TrialArthritis research & therapy2022

Observed efficacy and clinically important improvements in participants with osteoarthritis treated with subcutaneous tanezumab: results from a 56-week randomized NSAID-controlled study.

Tuhina Neogi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.